uniQure N.V. - Ordinary Shares (QURE): Price and Financial Metrics
GET POWR RATINGS... FREE!
QURE POWR Grades
- QURE scores best on the Value dimension, with a Value rank ahead of 99.89% of US stocks.
- QURE's strongest trending metric is Stability; it's been moving down over the last 179 days.
- QURE ranks lowest in Stability; there it ranks in the 7th percentile.
QURE Stock Summary
- With a price/earnings ratio of 2.51, uniQure NV P/E ratio is greater than that of about only 1.43% of stocks in our set with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, uniQure NV is reporting a growth rate of -347.26%; that's higher than merely 5.76% of US stocks.
- Revenue growth over the past 12 months for uniQure NV comes in at 1,296.82%, a number that bests 99.24% of the US stocks we're tracking.
- Stocks that are quantitatively similar to QURE, based on their financial statements, market capitalization, and price volatility, are FIXX, VIR, CDAK, CALA, and MRNS.
- Visit QURE's SEC page to see the company's official filings. To visit the company's web site, go to www.uniqure.com.
QURE Valuation Summary
- In comparison to the median Healthcare stock, QURE's price/sales ratio is 28.95% lower, now standing at 2.7.
- Over the past 54 months, QURE's price/earnings ratio has gone up 6.6.
- QURE's price/sales ratio has moved down 3.7 over the prior 54 months.
Below are key valuation metrics over time for QURE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| QURE | 2021-08-31 | 2.7 | 2.1 | 4.4 | 2.6 |
| QURE | 2021-08-30 | 2.6 | 2.1 | 4.4 | 2.5 |
| QURE | 2021-08-27 | 2.7 | 2.1 | 4.5 | 2.6 |
| QURE | 2021-08-26 | 2.6 | 2.1 | 4.3 | 2.5 |
| QURE | 2021-08-25 | 2.7 | 2.1 | 4.4 | 2.6 |
| QURE | 2021-08-24 | 2.6 | 2.0 | 4.3 | 2.5 |
QURE Growth Metrics
- Its 5 year price growth rate is now at 899.53%.
- Its 5 year cash and equivalents growth rate is now at 158.14%.
- Its 3 year price growth rate is now at 794.79%.
The table below shows QURE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 524.002 | 287.959 | 329.589 |
| 2021-09-30 | 500.397 | 297.874 | 320.682 |
| 2021-06-30 | 500.197 | 303.322 | 303.438 |
| 2021-03-31 | 37.864 | -143.148 | -138.581 |
| 2020-12-31 | 37.514 | -134.828 | -125.024 |
| 2020-09-30 | 6.053 | -123.66 | -165.751 |
QURE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- QURE has a Quality Grade of C, ranking ahead of 27.42% of graded US stocks.
- QURE's asset turnover comes in at 0.884 -- ranking 28th of 682 Pharmaceutical Products stocks.
- OVID, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with QURE.
The table below shows QURE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.884 | 0.954 | 1.955 |
| 2021-06-30 | 1.088 | 0.954 | 2.048 |
| 2021-03-31 | 0.105 | 1.000 | -1.161 |
| 2020-12-31 | 0.101 | 1.000 | -1.210 |
| 2020-09-30 | 0.015 | 1.000 | -1.522 |
| 2020-06-30 | 0.012 | 1.000 | -1.234 |
QURE Price Target
For more insight on analysts targets of QURE, see our QURE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $66.92 | Average Broker Recommendation | 1.37 (Strong Buy) |
QURE Stock Price Chart Interactive Chart >
QURE Price/Volume Stats
| Current price | $18.39 | 52-week high | $38.80 |
| Prev. close | $18.47 | 52-week low | $12.52 |
| Day low | $17.96 | Volume | 68,644 |
| Day high | $18.42 | Avg. volume | 582,757 |
| 50-day MA | $15.18 | Dividend yield | N/A |
| 200-day MA | $21.63 | Market Cap | 857.86M |
uniQure N.V. - Ordinary Shares (QURE) Company Bio
uniQure is a biopharmaceutical company, developing adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company was founded in 1998 and is based in Amsterdam, the Netherlands.
Latest QURE News From Around the Web
Below are the latest news stories about uniQure NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington''s DiseaseLEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE ), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington''s disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany. "We are very pleased to expand the clinical development of AMT-130 and to build on our ongoing experience in the Phase I/II clinical trial in the United States," stated Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. "We expect to complete patient enrollment in this... |
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseLEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany. |
Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-associated virus five (AAV5)-based gene therapy for people living with hemophilia B, a life-threatening bleeding disorder. Following a single infusion of etranacogene dezaparvovec, participants experienced a stable and durable increase in mean Factor IX (FIX) activity and hemostatic protection at 18 |
Everence Capital Management Inc Buys LyondellBasell Industries NV, Colgate-Palmolive Co, Match ...Goshen, IN, based Investment company Everence Capital Management Inc (Current Portfolio) buys LyondellBasell Industries NV, Colgate-Palmolive Co, Match Group Inc, Activision Blizzard Inc, Merck Inc, sells CBRE Group Inc, JPMorgan Chase, Johnson Controls International PLC, The Estee Lauder Inc, Republic Services Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Everence Capital Management Inc. |
Top Biotech Stocks for Q1 2022The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline. |
QURE Price Returns
| 1-mo | 28.06% |
| 3-mo | -5.45% |
| 6-mo | -11.33% |
| 1-year | -40.29% |
| 3-year | -76.05% |
| 5-year | 197.09% |
| YTD | -11.33% |
| 2021 | -42.60% |
| 2020 | -49.58% |
| 2019 | 148.65% |
| 2018 | 47.12% |
| 2017 | 249.82% |
Continue Researching QURE
Want to see what other sources are saying about uniQure NV's financials and stock price? Try the links below:uniQure NV (QURE) Stock Price | Nasdaq
uniQure NV (QURE) Stock Quote, History and News - Yahoo Finance
uniQure NV (QURE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...